Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
Oslo, 12 October 2020: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announce that the European Patent Office has granted European Patent no 3293201. The patent covers the use of ONCOS-102 in combination with checkpoint inhibitors.Torbjørn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this European patent has been granted, further strengthening Targovax's intellectual property portfolio covering the very important combination of ONCOS-102